Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
614 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04205812 | Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer(POD1UM-304) | completed | Phase 3 | 583 | Incyte CorporationINDUSTRY | 17 | Jul 6, 2026 | clinicaltrials |
| NCT04523493 | Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC | active not recruiting | Phase 3 | 530 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 5 | Jul 6, 2026 |
| clinicaltrials |
| NCT04248829 | Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) | completed | Phase 3 | 393 | Yuhan CorporationINDUSTRY | 13 | Jun 29, 2026 | clinicaltrials |
| NCT03088540 | Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 712 | Regeneron PharmaceuticalsINDUSTRY | 24 | Jun 25, 2026 | clinicaltrials |
| NCT03872401 | Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke(VESALIUS-CV) | completed | Phase 3 | 12,301 | AmgenINDUSTRY | 33 | Jun 25, 2026 | clinicaltrials |
| NCT04529772 | A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)(ESCALADE) | active not recruiting | Phase 3 | 611 | Acerta Pharma BVINDUSTRY | 23 | Jun 25, 2026 | clinicaltrials |
| NCT04961996 | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | active not recruiting | Phase 3 | 4,170 | Hoffmann-La RocheINDUSTRY | 54 | Jun 17, 2026 | clinicaltrials |
| NCT04181788 | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies | completed | Phase 1 / Phase 2 | 155 | PfizerINDUSTRY | 6 | Jun 15, 2026 | clinicaltrials |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy(Viale-a) | active not recruiting | Phase 3 | 443 | AbbVieINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04607421 | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | active not recruiting | Phase 3 | 841 | PfizerINDUSTRY | 29 | Jun 11, 2026 | clinicaltrials |
| NCT04014205 | A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies | active not recruiting | Phase 1 / Phase 2 | 81 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 4 | Jun 8, 2026 | clinicaltrials |
| NCT07624877 | Comparative Evaluation of Intraneuroma and Perineuroma Botulinum Toxin Type A Injection Techniques for Chronic Neuroma Pain After Combat-Related Amputation(IN-PERI NEUROM) | not yet recruiting | N/A | 100 | Ukrainian Society of Regional Anesthesia and Pain TherapyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07624890 | Ultrasound-Guided Platelet-Rich Plasma Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation(PRP-NEUROMA) | not yet recruiting | N/A | 100 | Ukrainian Society of Regional Anesthesia and Pain TherapyOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07618689 | Proximal Nerve Cryoablation Versus Perineuroma Cryoablation for Chronic Neuroma Pain After Combat-Related Amputation(AXON-FREEZE) | not yet recruiting | N/A | 50 | Ukrainian Society of Regional Anesthesia and Pain TherapyOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02972840 | A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL | active not recruiting | Phase 3 | 635 | Acerta Pharma BVINDUSTRY | 27 | Jun 1, 2026 | clinicaltrials |
| NCT02075840 | A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants(ALEX) | completed | Phase 3 | 303 | Hoffmann-La RocheINDUSTRY | 29 | May 29, 2026 | clinicaltrials |
| NCT07536841 | Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis(ОС26) | recruiting | — | 82 | Military Medical Clinical Center of the Southern Region, UkraineOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT04704934 | Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | active not recruiting | Phase 3 | 490 | Daiichi SankyoINDUSTRY | 24 | May 27, 2026 | clinicaltrials |
| NCT05064059 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | completed | Phase 3 | 441 | Merck Sharp & Dohme LLCINDUSTRY | 21 | May 26, 2026 | clinicaltrials |
| NCT03260894 | Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | completed | Phase 3 | 129 | Incyte CorporationINDUSTRY | 20 | May 22, 2026 | clinicaltrials |
| NCT05043090 | Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC(SAMETA) | active not recruiting | Phase 3 | 148 | AstraZenecaINDUSTRY | 25 | May 22, 2026 | clinicaltrials |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 130 | GenmabINDUSTRY | 20 | May 19, 2026 | clinicaltrials |
| NCT03409614 | Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer | completed | Phase 3 | 789 | Regeneron PharmaceuticalsINDUSTRY | 18 | May 18, 2026 | clinicaltrials |
| NCT04002297 | A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation(MANGROVE) | active not recruiting | Phase 3 | 510 | BeOne MedicinesINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT04380636 | Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | active not recruiting | Phase 3 | 870 | Merck Sharp & Dohme LLCINDUSTRY | 26 | May 15, 2026 | clinicaltrials |
| NCT04524273 | Myasthenia Gravis Inebilizumab Trial(MINT) | active not recruiting | Phase 3 | 238 | AmgenINDUSTRY | 19 | May 15, 2026 | clinicaltrials |
| NCT04195750 | A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) | active not recruiting | Phase 3 | 755 | Merck Sharp & Dohme LLCINDUSTRY | 23 | May 14, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT04746924 | A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer | terminated | Phase 3 | 669 | BeiGeneINDUSTRY | 19 | May 12, 2026 | clinicaltrials |
| NCT04241185 | Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) | active not recruiting | Phase 3 | 520 | Merck Sharp & Dohme LLCINDUSTRY | 25 | May 1, 2026 | clinicaltrials |
| NCT03155997 | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer(monarchE) | active not recruiting | Phase 3 | 5,637 | Eli Lilly and CompanyINDUSTRY | 38 | Apr 24, 2026 | clinicaltrials |
| NCT02296125 | AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(FLAURA) | completed | Phase 3 | 674 | AstraZenecaINDUSTRY | 30 | Apr 21, 2026 | clinicaltrials |
| NCT01630733 | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer(ENSPIRIT) | completed | Phase 3 | 664 | Achieve Life SciencesINDUSTRY | 14 | Apr 15, 2026 | clinicaltrials |
| NCT03937154 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer | active not recruiting | Phase 3 | 145 | AmgenINDUSTRY | 18 | Apr 7, 2026 | clinicaltrials |
| NCT04824092 | Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients(frontMIND) | active not recruiting | Phase 3 | 899 | Incyte CorporationINDUSTRY | 29 | Apr 1, 2026 | clinicaltrials |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | active not recruiting | Phase 3 | 354 | TakedaINDUSTRY | 24 | Mar 30, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT04472598 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis(TRANSFORM-1) | completed | Phase 3 | 252 | AbbVieINDUSTRY | 25 | Mar 23, 2026 | clinicaltrials |
| NCT03070392 | Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | completed | Phase 2 | 378 | Immunocore LtdINDUSTRY | 14 | Mar 17, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT03164616 | Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).(POSEIDON) | active not recruiting | Phase 3 | 1,186 | AstraZenecaINDUSTRY | 19 | Mar 13, 2026 | clinicaltrials |
| NCT03221426 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | completed | Phase 3 | 1,007 | Merck Sharp & Dohme LLCINDUSTRY | 24 | Mar 9, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT04884360 | D9319C00001- 1L OC Mono Global RCT(MONO-OLA1) | active not recruiting | Phase 3 | 366 | AstraZenecaINDUSTRY | 10 | Mar 2, 2026 | clinicaltrials |
| NCT01602380 | A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.(FALCON) | completed | Phase 3 | 462 | AstraZenecaINDUSTRY | 20 | Feb 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials